CAR-T, TCR Lentivirus
Note: All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
1. Understanding CAR-T?
Chimeric Antigen Receptors (CARs) are used to modify T cells, enabling them to produce a unique structure on their surface. This structure is composed of two parts: the antigen-binding and the T cell activation components.
The antigen-binding component, similar to an antibody, targets a specific antigen on the surface of a tumor. The antigen-binding moieties are typically derived from single-chain variable fragments (scFvs) of antibodies (for instance, those targeting a tumor surface antigen), Fab segments, or natural ligands that bind to their cognate receptor.
The activation component is made up of a chimeric molecule activation domain (found in 1st generation CARs), or a fusion containing both activating and co-stimulatory properties (found in 2nd generation CARs). The 2nd-generation CARs include the CD3-ζ chain and the cytoplasmic domain of a co-stimulatory receptor such as CD28, 4-1BB, CD80, or CD40L. The so-called 3rd-generation of CARs incorporate two co-stimulatory domains along with an activation domain in their cytoplasmic domain.
CAR-modified T cells are tumor-targeted T cells that have been enhanced for expansion and persistence within the tumor microenvironment, thus rapidly evolving as a potential cancer immunotherapy. The expression of cytokines in CAR-T cells can further modify the tumor microenvironment, greatly enhancing this approach. For instance, CD19-targeted, CAR-modified T cells expressing IL-12 have shown greater efficacy than CAR-modified T cells alone.
2. Understanding TCRs?
T cell receptors (TCRs) are a group of proteins found on T cells that bind to certain antigens (proteins) found on abnormal cells, cancer cells, cells from other organisms, and cells infected with a virus or another microorganism. This interaction causes the T cells to attack these cells and helps the body fight infection, cancer, or other diseases.
Unlike CAR-T cell therapy, which involves engineering synthetic receptors, TCR cell therapy utilizes naturally occurring TCRs that recognize specific antigens.
TCR engages HLA-peptide complexes and needs to be matched to the patient’s haplotype. CARs however do not require antigen processing and presentation by HLA. CARs are limited to recognizing cell surface antigens, whereas TCRs recognize both cell surface and intracellular proteins.
3. Gentarget’s CAR lentivirus Structure
4. Gentarget’s CAR lentivirus Structure
Gentarget has developed a series of CAR-T and TCR products for a variety of targets: CD19, CD20, CD22, HER2, BCMA HLA-A2, MART-1, NY-ESO1, and more, carrying different fluorescent or/and antibiotic selection marker. See our Lentivector map scheme above.
See products listed below, or click CAR-T Lentivirus Manual, TCR-Lentivirus, and click Anti-CD19 CAR-T Manual to see all products.
We also provide services to generate your desired CAR construct / lentivirus. Please contact us for service inquiries.